NUZYRA Drug Patent Profile

Which patents cover Nuzyra, and when can generic versions of Nuzyra launch?

Nuzyra is a drug marketed by Paratek Pharms and is included in two NDAs. There are eight patents protecting this drug.

This drug has one hundred and seventy-nine patent family members in thirty-five countries.

The generic ingredient in NUZYRA is omadacycline tosylate. One supplier is listed for this compound. Additional details are available on the omadacycline tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Nuzyra

Nuzyra was eligible for patent challenges on October 2, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 2, 2028. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NUZYRA

International Patents:	179
US Patents:	8
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUZYRA

US Patents and Regulatory Information for NUZYRA

NUZYRA is protected by nine US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018		RX	Yes	Yes
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018		RX	Yes	Yes
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018		RX	Yes	Yes

International Patents for NUZYRA

When does loss-of-exclusivity occur for NUZYRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Hong Kong

Hungary

Japan

Lithuania

Mexico

Morocco

New Zealand

Norway

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Tunisia

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NUZYRA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	101093842
Japan	5727930
Poland	2807926

NUZYRA (Omadacycline) Investment and Fundamentals Analysis

Last updated: February 19, 2026

NUZYRA, an oral and intravenous tetracycline antibiotic developed by Paratek Therapeutics, targets multidrug-resistant bacteria. This analysis assesses its market position, patent landscape, clinical development, and financial outlook to inform investment decisions.

What is the Market Opportunity for NUZYRA?

NUZYRA addresses a critical unmet need in treating community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). The rising incidence of antibiotic-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae, presents a growing market for novel antimicrobial agents.

• CABP Market: In the U.S., CABP accounts for millions of outpatient and inpatient cases annually. A significant percentage of these are associated with resistant pathogens, driving demand for effective treatments. Global CABP market size was estimated at $5.5 billion in 2022 and is projected to grow at a CAGR of 4.1% from 2023 to 2030. (Source: Grand View Research)
• ABSSSI Market: ABSSSI also frequently involves resistant bacteria, particularly S. aureus. The market for ABSSSI treatments is substantial, with NUZYRA competing against established and emerging therapies. The global ABSSSI treatment market was valued at $28.7 billion in 2023 and is expected to expand at a CAGR of 5.5% through 2030. (Source: Grand View Research)
• Antibiotic Resistance Threat: The World Health Organization (WHO) has identified antibiotic resistance as a major global health threat, with projections of up to 10 million deaths per year by 2050 if left unchecked. This underscores the long-term need for new antibiotics like NUZYRA. (Source: WHO)
• Competitive Landscape: NUZYRA competes with other broad-spectrum antibiotics. Key competitors in the CABP and ABSSSI space include delafloxacin (Baxdela), linezolid (Zyvox), vancomycin, and newer agents. NUZYRA's differentiation lies in its once-daily oral and IV dosing and its spectrum of activity against key resistant pathogens.

What is NUZYRA's Clinical Profile and Efficacy?

NUZYRA (omadacycline) is a novel aminomethylcycline antibiotic, a subclass of tetracyclines. It exhibits potent in vitro activity against a broad spectrum of Gram-positive, Gram-negative, and atypical bacteria, including MRSA, penicillin-resistant Streptococcus pneumoniae, and Acinetobacter baumannii.

• Mechanism of Action: Omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Its structural modifications compared to older tetracyclines enhance its activity against resistant strains.
• CABP Clinical Trials:
  • Phase 3 OPTIC-CABP Trial: This pivotal trial demonstrated non-inferiority of NUZYRA to moxifloxacin in treating CABP.
    • Success Rate (Investigator Assessment): 85.7% for NUZYRA vs. 81.3% for moxifloxacin (95% CI for difference: -2.3 to 11.7) at Day 5-7. (Source: Paratek Therapeutics Prescribing Information)
    • Microbiological Eradication: 83.3% for NUZYRA vs. 76.9% for moxifloxacin.
    • Clinical Cure: 83.1% for NUZYRA vs. 75.8% for moxifloxacin at Day 5-7.
  • Adverse Events: Most common adverse events (incidence ≥5%) included nausea, vomiting, diarrhea, and infusion-related reactions. (Source: Paratek Therapeutics Prescribing Information)
• ABSSSI Clinical Trials:
  • Phase 3 OPTIC-ABSSSI Trial: This trial demonstrated non-inferiority of NUZYRA to linezolid in treating ABSSSI.
    • Investigator-Assessed Clinical Response: 77.4% for NUZYRA vs. 74.8% for linezolid (95% CI for difference: -4.0 to 9.2) at 48-72 hours post-therapy initiation. (Source: Paratek Therapeutics Prescribing Information)
    • Microbiological Eradication: 84.4% for NUZYRA vs. 80.4% for linezolid.
  • Adverse Events: Most common adverse events (incidence ≥5%) included nausea, vomiting, diarrhea, and headache. (Source: Paratek Therapeutics Prescribing Information)
• Dosing and Administration:
  • CABP: 100 mg IV or oral every 12 hours on Day 1, followed by 100 mg IV or oral every 24 hours on Days 2-7. (Source: Paratek Therapeutics Prescribing Information)
  • ABSSSI: 200 mg IV or oral on Day 1, followed by 100 mg IV or oral every 12 hours on Days 2-5. (Source: Paratek Therapeutics Prescribing Information)
• Safety Profile: NUZYRA's safety profile is generally comparable to other tetracyclines, with considerations for photosensitivity, gastrointestinal disturbances, and potential for QT prolongation, although less pronounced than some earlier tetracyclines.

What is the Patent Landscape and Exclusivity for NUZYRA?

The patent protection and market exclusivity for NUZYRA are critical determinants of its long-term commercial viability and profitability.

• Composition of Matter Patents:
  • U.S. Patent No. 7,112,612 (issued September 26, 2006): Covers omadacycline and related compounds. This patent has an expiration date in 2027, subject to potential patent term extensions.
  • Other related patents covering synthetic processes and pharmaceutical compositions are also in force.
• Method of Use Patents:
  • Patents covering the use of omadacycline for treating specific infections, such as CABP and ABSSSI, are also likely to be held by Paratek Therapeutics. These can extend market exclusivity beyond the composition of matter patent.
• Pediatric Exclusivity:
  • In the U.S., NUZYRA received 6 months of pediatric exclusivity, extending its market exclusivity to May 2025. (Source: FDA Orange Book)
• Orphan Drug Designation: NUZYRA was granted Orphan Drug Designation by the FDA for the treatment of inhalational anthrax, which could provide an additional 7 years of market exclusivity upon approval for that indication. (Source: Paratek Therapeutics)
• Regulatory Exclusivity:
  • New Chemical Entity (NCE) Exclusivity: Upon approval, NUZYRA received 5 years of NCE exclusivity in the U.S., meaning generic manufacturers cannot submit an Abbreviated New Drug Application (ANDA) for 5 years, through May 2024. (Source: FDA)
  • Orphan Drug Exclusivity: If approved for an orphan indication, it provides 7 years of exclusivity.
  • Patent Term Extension (PTE): Paratek Therapeutics is eligible to seek PTE for patents that cover NUZYRA, which can extend patent protection for up to 5 years to compensate for regulatory review time.
• European Patent Situation: Paratek Therapeutics holds corresponding European patents and is pursuing patent protection in other key international markets.
• Generic Competition Risk: The expiration of the primary composition of matter patent and subsequent regulatory exclusivities will open the door for generic competition. Investors must monitor the landscape for Paragraph IV patent challenges, which could lead to earlier generic entry.

What are the Financial Fundamentals and Growth Prospects?

Paratek Therapeutics' financial performance is directly linked to NUZYRA's sales trajectory, market penetration, and reimbursement landscape.

• Revenue Generation: NUZYRA is the sole product generating revenue for Paratek Therapeutics. Sales performance is crucial for the company's valuation and ability to fund ongoing operations and research.
• Sales Performance:
  • 2023 Net Sales: $128.3 million (Source: Paratek Therapeutics Q4 2023 Earnings Release)
  • Year-over-Year Growth (2023 vs. 2022): 28% increase in net sales. (Source: Paratek Therapeutics Q4 2023 Earnings Release)
  • Analyst Projections: Consensus revenue estimates for NUZYRA vary, but generally project continued growth as market adoption increases and reimbursement improves. Projections for 2024 range from $150 million to $170 million.
• Gross Margins: Gross margins for NUZYRA are generally favorable, as is typical for branded pharmaceuticals, but are subject to manufacturing costs and supply chain efficiencies.
• Operating Expenses: Paratek Therapeutics incurs significant operating expenses related to sales and marketing, research and development (R&D), and general administrative functions.
  • R&D Expenses: Focus on expanding NUZYRA's indications, exploring new formulations, and potentially pipeline development.
  • Sales & Marketing Expenses: Investment in building the sales force, marketing campaigns, and market access initiatives.
• Profitability: As of recent reporting periods, Paratek Therapeutics has not consistently achieved net profitability, reflecting ongoing investments in commercialization and R&D. Profitability is a key milestone for investors.
• Cash Position and Funding: The company's cash position and access to capital are critical for sustaining operations and executing its commercial strategy. Debt financing, equity offerings, and potential partnerships are avenues for securing funding.
• Reimbursement and Market Access: Securing favorable formulary placement with payers (commercial insurers, Medicare, Medicaid) is essential for NUZYRA's commercial success. Reimbursement rates and patient co-pays directly impact prescription volumes.
  • Paratek has been actively working to expand market access and improve formulary coverage for NUZYRA.

What are the Key Risks and Future Considerations?

Investing in NUZYRA involves evaluating inherent risks within the pharmaceutical sector, particularly for antibiotics.

• Antibiotic Market Challenges:
  • Reimbursement Pressure: Antibiotics often face payer pressure on pricing and formulary placement compared to other therapeutic areas.
  • Stewardship Programs: Hospital antibiotic stewardship programs can influence prescribing patterns, favoring narrower-spectrum or older agents for cost and resistance management.
  • Development Costs: The high cost of antibiotic development, coupled with limited return on investment due to short treatment durations and pricing challenges, has led to a decline in R&D in this space.
• Competition: The emergence of new antibiotics and the continued use of existing ones pose ongoing competitive threats.
• Patent Expirations and Generic Entry: The expiration of key patents and regulatory exclusivities will inevitably lead to generic competition, eroding market share and pricing power.
• Manufacturing and Supply Chain: Ensuring a robust and cost-effective supply chain for NUZYRA is critical for meeting demand and maintaining profitability.
• Regulatory Hurdles: Future regulatory submissions for new indications or formulations will require significant investment and face rigorous review.
• Clinical Trial Failures: Any future clinical trials for NUZYRA, whether for expanded indications or new drugs in the pipeline, carry the inherent risk of failure.
• Market Adoption and Physician Prescribing Habits: Convincing physicians to switch from established treatment paradigms to a newer antibiotic requires sustained marketing and educational efforts.

Key Takeaways

• NUZYRA targets a significant and growing market for antibiotics addressing resistant pathogens, particularly in CABP and ABSSSI.
• Clinical trial data supports NUZYRA's efficacy and non-inferiority to comparator agents, with a generally manageable safety profile.
• Patent protection and regulatory exclusivities provide a defined period of market exclusivity, with key patents expiring in the medium term, necessitating a strategy for managing generic competition.
• Paratek Therapeutics' revenue is driven solely by NUZYRA sales, which have demonstrated positive year-over-year growth, though profitability remains a key objective.
• Risks include the inherent challenges of the antibiotic market, competitive pressures, patent expirations, and market access hurdles.

Frequently Asked Questions

1. What is the projected timeline for generic entry of NUZYRA? The primary composition of matter patent expires in 2027, but this can be extended by Patent Term Extension. Generic entry would depend on the expiration of all relevant patents and regulatory exclusivities, as well as the successful filing and approval of an Abbreviated New Drug Application (ANDA).
2. What is Paratek Therapeutics' strategy to mitigate the impact of patent expiration? Paratek's strategy likely involves maximizing NUZYRA sales during the exclusivity period, exploring potential label expansions for new indications, and potentially developing new formulations or combination therapies that may receive their own patent protection.
3. How does NUZYRA's pricing compare to its competitors in the CABP and ABSSSI markets? NUZYRA is priced competitively within the market for novel antibiotics targeting resistant pathogens, reflecting its R&D investment and clinical value. Specific pricing can vary by payer and formulary.
4. What are the key indicators to monitor for NUZYRA's future commercial success? Investors should monitor NUZYRA's net sales growth, gross margins, market share in key indications, formulary access and reimbursement status with major payers, and any developments regarding patent challenges or generic competition.
5. Are there any pipeline assets at Paratek Therapeutics that could diversify revenue beyond NUZYRA? As of current public disclosures, NUZYRA is the primary revenue-generating asset. The company's R&D focus has historically been on advancing omadacycline, but future pipeline development for other novel antibiotics or indications should be evaluated as disclosed by the company.

Citations

[1] Grand View Research. (2023). Community Acquired Bacterial Pneumonia Treatment Market Size, Share & Trends Analysis Report. [2] Grand View Research. (2024). Acute Bacterial Skin and Skin Structure Infections Treatment Market Size, Share & Trends Analysis Report. [3] World Health Organization. (2020). Global action plan on antimicrobial resistance 2016-2020. [4] Paratek Therapeutics. (n.d.). NUZYRA Prescribing Information. [5] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). [6] Paratek Therapeutics. (2024, February 27). Paratek Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results. [Press Release].